News Medical on MSN17h
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
New Alzheimer’s drug donanemab rejected for widespread use in NHS
A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns
A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns.
Outsourcing-pharma3d
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
The Financial Express1d
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.
STAT3d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
openaccessgovernment3d
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...
Eli Lilly Alzheimer's Drug Faces Tough Road In UK, Price Watchdog NICE Says Donanemab Is Not Cost-Effective
Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.
The Daily Telegraph3d
Alzheimer’s wonder drug blocked on NHS over cost
Donanemab has been described as game-changing and research showed it slowed the progression of Alzheimer’s by 35 per cent. Scientists said it could mean patients were able to live at home with a ...